Clinical Guides
Portal Hypertension
A clinically focused clinical guide to recognizing, staging and managing portal hypertension, with practical Indian pathways for cirrhosis, non-cirrhotic disease, acute bleeding, TIPS and transplantation.
MedNext Academy | 14 min read
Portal Hypertension
A clinically focused clinical guide to recognizing, staging and managing portal hypertension, with practical Indian pathways for cirrhosis, non-cirrhotic disease, acute bleeding, TIPS and transplantation.
Summary
Portal hypertension is a pathological increase in pressure across the portal venous system, most often caused by cirrhosis but also produced by prehepatic, presinusoidal and posthepatic disorders. In cirrhosis, fixed architectural resistance combines with dynamic intrahepatic vasoconstriction and increased splanchnic inflow. The resulting collateral circulation may form gastro-oesophageal varices, while clinically significant portal hypertension drives ascites, splenomegaly, thrombocytopenia, portal hypertensive gastropathy, hepatic encephalopathy and decompensation. Hepatic venous pressure gradient (HVPG) is the reference haemodynamic measure for sinusoidal disease: values at least 10 mmHg define clinically significant portal hypertension, and variceal bleeding generally requires a higher gradient. HVPG can be normal in important presinusoidal causes, so a normal result is not a universal exclusion test.
Management is not limited to finding varices. The clinician must establish cause and stage, identify compensated patients at risk of decompensation, prevent first bleeding where indicated, treat acute haemorrhage as a time-critical emergency, and recognize when portal decompression or liver transplantation is needed. In suitable compensated cirrhosis with clinically significant portal hypertension, a non-selective beta blocker (NSBB), preferably carvedilol in current consensus pathways, can reduce portal pressure and risk of decompensation. Endoscopic band ligation prevents bleeding from high-risk oesophageal varices when NSBB treatment is unsuitable, but does not treat the wider portal-hypertensive syndrome.
Non-invasive criteria reduce unnecessary endoscopy in defined populations, yet their aetiology, body-mass, device and validation limits matter. Acute suspected variceal bleeding requires resuscitation, restrictive red-cell transfusion, prompt vasoactive therapy, short-course antibacterial prophylaxis and endoscopy, followed by risk-based pre-emptive or rescue TIPS. Every recommendation must be adapted to blood pressure, renal function, encephalopathy risk, local microbiology, endoscopy and interventional-radiology access, and the person's transplant trajectory.
How Common Is It?
Portal hypertension is common among people with advanced chronic liver disease, but no single prevalence figure applies across stages or causes. Its frequency rises as fibrosis and cirrhosis progress. Varices develop in a substantial proportion of patients with cirrhosis, and their size and bleeding risk increase with decompensation. The measurable population also depends on whether studies use HVPG, endoscopy, elastography, imaging or clinical complications. Clinically significant portal hypertension may exist before ascites or bleeding, while splenomegaly and thrombocytopenia may provide the first clues. Conversely, isolated mild thrombocytopenia is not specific and should not be treated as a diagnosis.
India bears a large and heterogeneous chronic-liver-disease burden. Alcohol-associated liver disease, chronic hepatitis B and C, and metabolic dysfunction-associated steatotic liver disease all contribute to cirrhosis. Non-cirrhotic portal hypertension is particularly important in Indian differential diagnosis: portal vein thrombosis, extrahepatic portal venous obstruction and porto-sinusoidal vascular disease can produce major varices despite relatively preserved hepatic synthetic function. Budd-Chiari syndrome is another relevant vascular cause. Hospital cohorts overrepresent severe disease and cannot be converted into a national prevalence estimate without population sampling.
The burden is therefore better described clinically than with a false precise number. Portal hypertension accounts for emergency haematemesis and melaena, recurrent admissions, ascites procedures, infection, renal dysfunction and demand for transplant services. Geography and household resources affect whether compensated disease is detected before a first bleed. A useful service audit measures aetiology work-up, timely screening or validated non-invasive stratification, appropriate NSBB use, access to emergency vasoactive drugs and antibiotics, endoscopy within the recommended window, TIPS referral and transplant assessment. Counts based only on endoscopy miss people treated empirically with NSBBs and those unable to reach specialist care.
Risk Factors
The principal risk factor is advanced chronic liver disease, whatever the initiating injury. Ongoing alcohol exposure, uncontrolled viral hepatitis, metabolic disease with obesity or diabetes, autoimmune or cholestatic liver disease, and repeated hepatotoxic injury accelerate fibrosis and portal-pressure progression. A person with compensated advanced chronic liver disease can develop clinically significant portal hypertension without obvious stigmata. Risk of decompensation is influenced by liver stiffness, platelet count, synthetic function, previous ascites or encephalopathy, active alcohol use, infection and coexisting kidney or cardiac disease. These factors guide surveillance and referral; they do not replace aetiological diagnosis.
Prehepatic and presinusoidal risks require separate reasoning. Portal vein thrombosis may accompany cirrhosis, malignancy, pancreatitis, abdominal infection, surgery or prothrombotic states. Extrahepatic portal venous obstruction may present in childhood or young adulthood with splenomegaly and bleeding. Schistosomiasis is globally important but is not the usual assumption in India without residence or exposure in an endemic area. Porto-sinusoidal vascular disease can be associated with immune, haematological, infectious, genetic or medication-related conditions, although no cause is found in some patients. Posthepatic pressure elevation follows hepatic venous outflow obstruction, constrictive pericarditis or severe right-sided cardiac disease.
Once varices exist, bleeding risk rises with larger size, red wale marks and advanced hepatic dysfunction. Bacterial infection, acute kidney injury and continued alcohol use can precipitate decompensation. Portal pressure is only one determinant: mucosal trauma, haemostasis, collateral anatomy and treatment adherence matter. Risk also arises from care gaps—unrecognized cirrhosis, inappropriate NSAIDs, excessive diuresis, missed surveillance and use of NSBBs despite persistent hypotension or hepatorenal syndrome. Anticoagulation is not automatically prohibited in portal hypertension; its indication, clot age, bleeding prophylaxis and liver function require specialist balance rather than reflex withholding.
Diagnosis
History
Ask about jaundice, abdominal distension, ankle swelling, haematemesis, melaena, confusion, sleep reversal, weight loss, pruritus and reduced exercise tolerance. Establish alcohol exposure without moral judgement; viral risks, metabolic disease, transfusions, abdominal infection or surgery, pancreatitis, thrombosis and family history are relevant. Document previous endoscopy, banding, ascitic taps, spontaneous bacterial peritonitis, encephalopathy and transplant assessment. Reconcile beta blockers, diuretics, anticoagulants, antiplatelets, NSAIDs, herbal products and adherence. Acute bleeding history must include timing, volume, syncope, comorbidity and last oral intake without delaying resuscitation.
Examination
Assess airway, mental state, perfusion and haemodynamic stability first when bleeding or sepsis is possible. Look for sarcopenia, jaundice, bruising, spider angiomas, palmar erythema, parotid enlargement and alcohol-withdrawal signs. Examine for hepatomegaly or a small nodular liver, splenomegaly, abdominal-wall collaterals, ascites, oedema and asterixis. Fever, focal tenderness, hypoxia, raised jugular venous pressure or cardiac murmurs may redirect the cause or expose a precipitant. Rectal examination is selective; melaena can support upper gastrointestinal bleeding but absence does not exclude it.
Investigations
Obtain full blood count, liver profile, albumin, INR, renal function, electrolytes and aetiology-directed tests. Ultrasound with Doppler assesses liver morphology, spleen, ascites, portal-vein patency and flow; cross-sectional contrast imaging maps thrombosis, collaterals, tumours and anatomy before intervention. Transient elastography plus platelet count can stratify selected compensated cirrhosis, but cut-offs must match the validated aetiology and device. Endoscopy identifies oesophageal or gastric varices and portal hypertensive gastropathy when indicated. HVPG confirms and quantifies sinusoidal portal hypertension in expert centres but does not diagnose every presinusoidal disorder. Ascites requires diagnostic paracentesis at new presentation, hospital admission or clinical deterioration. Echocardiography is important when cardiac disease or TIPS is considered.
Differential Diagnosis
Portal hypertension is a syndrome, so the differential is organized by the anatomical level of resistance. Prehepatic obstruction includes acute or chronic portal vein thrombosis, splenic-vein thrombosis and extrinsic compression. Splenic-vein thrombosis may cause isolated gastric varices with otherwise normal portal pressure. Presinusoidal disorders include schistosomiasis, congenital hepatic fibrosis, sarcoidosis and porto-sinusoidal vascular disease. Sinusoidal disease is dominated by cirrhosis from alcohol, viral hepatitis, steatotic liver disease, autoimmune hepatitis or cholestatic conditions. Postsinusoidal and posthepatic causes include sinusoidal obstruction syndrome, Budd-Chiari syndrome, inferior vena-cava obstruction, constrictive pericarditis and severe right-heart failure.
Not every patient with ascites has portal hypertension. Heart failure, nephrotic syndrome, peritoneal malignancy, tuberculosis and pancreatic disease require fluid analysis and contextual evaluation. Serum-ascites albumin gradient supports pressure-related ascites but does not determine aetiology alone. Splenomegaly with thrombocytopenia can reflect haematological malignancy, infection, immune thrombocytopenia or hypersplenism from another cause. Abdominal-wall veins may be caused by inferior vena-cava obstruction; the direction and distribution of flow can help but imaging is definitive.
In acute upper gastrointestinal bleeding, peptic ulcer, erosive disease, malignancy, Mallory-Weiss tear and vascular lesions remain alternatives even in a person with cirrhosis. Treat suspected variceal haemorrhage early because delay is hazardous, then establish the lesion endoscopically. Portal hypertensive gastropathy and gastric antral vascular ectasia are distinct entities with different endoscopic appearances and management. A normal HVPG does not exclude prehepatic or presinusoidal portal hypertension because the wedged hepatic venous measurement reflects sinusoidal pressure. Finally, portal-vein thrombosis may be cause, consequence or complication of cirrhosis; imaging chronology, tumour assessment and thrombophilia context determine interpretation.
Management
Treat the cause and the portal-hypertensive state together. Achieve alcohol abstinence support, suppress or cure viral hepatitis when indicated, manage metabolic risk and provide disease-specific therapy for autoimmune or cholestatic disease. Nutrition, exercise against frailty, vaccination, avoidance of nephrotoxins and surveillance for hepatocellular carcinoma remain core cirrhosis care. In selected compensated advanced chronic liver disease, Baveno VII non-invasive criteria can rule in or rule out clinically significant portal hypertension; grey-zone patients need additional assessment rather than forced classification. Patients already receiving an effective NSBB to prevent decompensation may not need screening endoscopy solely to decide prophylaxis, while those unsuitable for NSBBs require endoscopic risk assessment.
Carvedilol is preferred in many compensated-cirrhosis pathways because it lowers intrahepatic resistance as well as splanchnic inflow. Traditional NSBBs remain options. High-risk oesophageal varices can be managed with NSBBs or endoscopic variceal ligation when NSBBs are contraindicated or not tolerated. Ascites is treated with salt-aware nutrition, diuretics and paracentesis with albumin when appropriate; recurrent ascites should prompt TIPS and transplant discussion. Encephalopathy, infection and renal dysfunction each require dedicated protocols.
Acute suspected variceal bleeding demands airway and circulation assessment, cautious crystalloid use, restrictive red-cell transfusion targeting haemoglobin about 7–8 g/dL in most patients, vasoactive therapy started immediately, and antibiotic prophylaxis adapted to allergy and local resistance. Perform endoscopy within twelve hours after initial resuscitation; band ligation is standard for oesophageal variceal bleeding. Consider pre-emptive TIPS within 72 hours, preferably 24, for validated high-risk groups, and rescue TIPS for uncontrolled haemorrhage. A self-expanding oesophageal stent or balloon tamponade is only a bridge in refractory bleeding where expertise exists. Secondary prevention combines NSBB therapy with repeat band ligation unless contraindicated.
Prescribing Information
NSBB prescribing is physiological, not a fixed-dose checklist. Carvedilol is commonly initiated at a low dose and titrated cautiously; traditional propranolol or nadolol may be titrated toward a safe resting heart rate while maintaining perfusion. Check baseline pulse, seated and standing blood pressure, renal function, sodium, asthma history, conduction disease and interacting medicines. Do not chase a heart-rate target through dizziness, acute kidney injury or hypotension. In ascites, reduce or stop NSBB treatment when systolic pressure remains below 90 mmHg, mean arterial pressure below 65 mmHg or hepatorenal syndrome–acute kidney injury develops, then reassess after recovery. Abrupt unsupervised cessation can be harmful.
For suspected acute variceal haemorrhage, start a vasoactive agent such as terlipressin, somatostatin or octreotide according to local protocol before endoscopy and continue for two to five days when haemostasis is achieved. Terlipressin can cause ischaemia, arrhythmia, hyponatraemia and respiratory complications; assess contraindications and monitor closely. Give short-course antibacterial prophylaxis from admission. Ceftriaxone is often preferred in advanced cirrhosis or where quinolone resistance is substantial, but allergy, local antibiogram, renal function and recent exposure must guide the exact regimen. Routine proton-pump inhibitor continuation is unnecessary after a purely variceal source is confirmed unless another indication exists.
Avoid indiscriminate plasma transfusion to correct INR: conventional INR does not measure the balanced haemostasis of cirrhosis, and volume can worsen portal pressure. Platelets, fibrinogen replacement or prothrombin complex concentrate require an individualized major-bleeding protocol rather than arbitrary normalization. Lactulose and rifaximin manage defined encephalopathy indications, not portal pressure itself. Diuretics require daily weight, renal and electrolyte monitoring. Anticoagulation for portal-vein thrombosis can be appropriate after specialist assessment; varices are a reason to coordinate prophylaxis and monitoring, not an automatic permanent contraindication.
When to Refer
Refer suspected compensated advanced chronic liver disease with thrombocytopenia, splenomegaly, collaterals or elastography evidence to a clinician who can establish clinically significant portal hypertension and its cause. The referral should include serial blood counts, liver and renal profiles, INR, aetiology testing, ultrasound-Doppler, elastography method and previous imaging. Endoscopy is required when non-invasive criteria do not safely avoid it, when NSBBs cannot be used, or when bleeding is suspected. Portal vein thrombosis, Budd-Chiari syndrome, unexplained non-cirrhotic portal hypertension and possible porto-sinusoidal vascular disease need hepatology and vascular-imaging expertise.
Urgent transfer is needed for active haematemesis or melaena, haemodynamic instability, encephalopathy, sepsis, acute kidney injury or rapidly accumulating ascites. A hospital without round-the-clock therapeutic endoscopy should activate a documented transfer pathway while beginning resuscitation, vasoactive treatment and antibiotics. Early discussion with a TIPS-capable centre is appropriate for Child-Pugh C disease up to 13 points, Child-Pugh B above 7 with active bleeding at endoscopy, uncontrolled haemorrhage, recurrent bleeding despite combination prophylaxis or recurrent ascites. TIPS candidacy requires cardiac, pulmonary, renal and encephalopathy assessment.
Transplant referral should not wait for irreversible multi-organ failure. First decompensation, recurrent ascites, variceal bleeding, encephalopathy, deteriorating synthetic function, liver cancer within transplant pathways or poor quality of life despite optimal treatment are prompts for assessment. MELD-based scores assist prioritization but do not replace clinical trajectory. In non-cirrhotic portal hypertension, transplantation is not routine when liver function is preserved; intervention targets the vascular problem and complications. Shared care should identify who monitors NSBB safety, arranges repeat ligation, performs cancer surveillance and responds to deterioration.
Red Flags
Haematemesis, coffee-ground vomiting, melaena, syncope or unexplained shock in someone with known or possible portal hypertension is an emergency. Protect the airway when consciousness is impaired or bleeding is massive, obtain large-bore access, cross-match blood and start the variceal-bleed bundle without waiting for endoscopy. Persistent bleeding after vasoactive and endoscopic therapy requires immediate rescue-TIPS discussion. Balloon tamponade must never become definitive ward treatment because aspiration, ulceration and perforation risks rise with time; it is a monitored bridge to haemostasis.
New fever, abdominal pain, hypotension, encephalopathy or renal deterioration in ascites suggests spontaneous bacterial peritonitis or another infection and mandates diagnostic paracentesis and cultures without delaying antibiotics in an unstable patient. Oliguria, rising creatinine, severe hyponatraemia or falling arterial pressure may herald hepatorenal syndrome. New portal-vein thrombosis, painful hepatomegaly or rapid ascites can indicate Budd-Chiari syndrome or malignant vascular invasion. Progressive jaundice, weight loss or a focal liver lesion requires prompt cancer evaluation.
Medication danger signs include symptomatic bradycardia, persistent hypotension, wheeze or acute kidney injury on an NSBB; chest pain, limb ischaemia, severe hyponatraemia or respiratory decline during terlipressin; and ototoxicity, electrolyte depletion or renal injury from aggressive diuresis. Do not interpret a falling haemoglobin as dilution without assessing ongoing bleeding. Do not correct INR to an arbitrary normal value with large plasma volumes. After TIPS, new confusion, heart failure, hypoxaemia or worsening liver tests requires urgent review. Any patient with recurrent bleeding or decompensation who has never been assessed for transplantation has an unresolved red flag in the care pathway.
Indian Clinical Context
Indian presentations span metropolitan transplant centres and districts without emergency endoscopy. A safe pathway therefore starts with capabilities that change immediate care: recognition of chronic liver disease, blood pressure and mental-state assessment, haemoglobin and renal testing, ultrasound-Doppler where available, and early referral. Cirrhosis from alcohol, hepatitis B or C and metabolic disease must be actively sought, but a young person with massive splenomegaly, preserved albumin and recurrent bleeding should raise extrahepatic portal venous obstruction or other non-cirrhotic portal hypertension. Tuberculosis, abdominal infection and pancreatitis can contribute to vascular disease; schistosomiasis requires a genuine exposure history rather than a textbook reflex.
Transient elastography and platelet criteria can spare some endoscopies, yet the Baveno thresholds were not validated equally across every aetiology, obesity category or device. Where high-quality elastography is unavailable, clinicians should not manufacture reassurance from a single platelet count. Conversely, universal repeated endoscopy may be unrealistic. Document whether the chosen pathway is NSBB-based, endoscopy-based or a specialist non-invasive algorithm, and create recall systems. Generic carvedilol and propranolol are widely available, but titration without blood-pressure and renal review is unsafe.
For bleeding, every receiving hospital should stock a protocol-defined vasoactive drug and antibiotic, know its blood-bank limits and maintain transfer contacts for therapeutic endoscopy and TIPS. ESGE cascade guidance explicitly acknowledges resource stratification, but a lower-resource setting does not justify omitting resuscitation, early vasoactive treatment or infection prophylaxis. Interventional radiology and transplantation remain concentrated and costly; referral must begin before repeated crises. Evidence from international cirrhosis cohorts should be applied transparently: Indian aetiological mix, antimicrobial resistance, late presentation, affordability and non-cirrhotic disease may alter implementation. Patient instructions should be written in the preferred language and clearly distinguish scheduled review from emergency bleeding symptoms.
NMC Competency Mapping
Portal hypertension integrates undergraduate physiology, pathology, pharmacology, medicine, surgery and emergency care. NMC physiology outcomes on hepatic circulation and liver function support the pressure-gradient concept. Pathology outcomes on cirrhosis explain architectural resistance, collateral formation and decompensation. General Medicine Topic 5 includes systematic history and examination in liver disease, interpretation of liver tests and principles of managing cirrhosis, portal hypertension and liver failure. A clinical case can test recognition of variceal bleeding, ascites, splenomegaly and encephalopathy while requiring learners to stabilize before seeking a complete diagnostic label.
Pharmacology learning includes rational use and adverse-effect monitoring of beta blockers, vasoactive drugs, antibiotics, diuretics and therapies for encephalopathy. Surgery and radiology teaching can connect portosystemic collaterals, Doppler findings, endoscopic haemostasis, TIPS and transplantation. Communication competencies are equally relevant: alcohol history should be non-stigmatizing; prognosis, rebleeding, adherence and transplant referral require shared decisions. Infection control and blood-product stewardship belong within the acute-bleed scenario.
The expected MBBS level is to recognize the syndrome, distinguish compensated from decompensated disease, order safe first-line investigations, begin emergency measures under protocol and refer promptly. Independent selection of a TIPS candidate, HVPG interpretation, anticoagulation for portal-vein thrombosis or transplantation listing requires specialist supervision. Learners should know that non-invasive cut-offs apply only within validated populations and that INR is not a simple bleeding-risk meter in cirrhosis. Competence must be demonstrated clinically; this draft is an educational synthesis, not certification, a bedside order set or authority to undertake endoscopy.
Key Exam Pearls for NEET PG
Clinically significant portal hypertension is defined by HVPG at least 10 mmHg in sinusoidal disease; variceal bleeding usually occurs at gradients of 12 mmHg or more. HVPG may be normal in prehepatic or presinusoidal disease. Portal hypertension results from increased intrahepatic resistance plus increased splanchnic inflow. Splenomegaly, thrombocytopenia, ascites, collaterals and varices are clues, not interchangeable diagnostic tests. A high serum-ascites albumin gradient supports portal-pressure-related ascites. Isolated gastric varices suggest splenic-vein thrombosis among the differentials.
For selected compensated viral-, alcohol- or non-obese steatotic-related advanced liver disease, liver stiffness at or below 15 kPa with platelets at least 150 × 10^9/L can rule out clinically significant portal hypertension, while stiffness at or above 25 kPa can rule it in; remember population and device limitations. Carvedilol is often preferred for compensated clinically significant portal hypertension. If NSBBs cannot be used, screen for high-risk varices and use band ligation where indicated. In ascites, persistent systolic pressure below 90 mmHg, MAP below 65 mmHg or HRS-AKI prompts NSBB dose reduction or cessation.
Acute variceal bleeding answers follow a bundle: resuscitate, restrictive red-cell transfusion, start vasoactive therapy and antibiotics immediately, then endoscopy within twelve hours after stabilization. Band ligation treats oesophageal variceal bleeding. High-risk patients may need pre-emptive TIPS within 72 hours, preferably 24; failed combined treatment needs rescue TIPS. Secondary prophylaxis is NSBB plus repeat ligation. Do not routinely use large-volume plasma merely to normalize INR. TIPS reduces portal pressure but can precipitate encephalopathy and cardiac decompensation. Recurrent decompensation should trigger transplant assessment, not endless isolated treatment of each complication.
Frequently Asked Questions
Can portal hypertension be diagnosed from a low platelet count and enlarged spleen alone?
No. Those findings raise suspicion but are not specific. Diagnosis integrates liver disease, Doppler or cross-sectional imaging, endoscopy when indicated and validated elastography criteria; HVPG is useful for sinusoidal disease. Aetiology matters because presinusoidal portal hypertension may have a normal HVPG and preserved synthetic function.
Does every patient with cirrhosis need repeated screening endoscopy for oesophageal varices?
Not necessarily. Validated non-invasive criteria can avoid endoscopy in selected compensated disease, and a person already receiving an effective NSBB to prevent decompensation may not need endoscopy solely to choose prophylaxis. Limits related to aetiology, obesity, device, platelet count and drug tolerance must be respected.
What treatment should begin before endoscopy in suspected acute variceal bleeding?
After immediate airway and circulation assessment, begin a protocol-defined vasoactive agent and short-course antibacterial prophylaxis, use a restrictive red-cell strategy in most patients, and arrange endoscopy within twelve hours after resuscitation. Do not wait for endoscopic proof when clinical suspicion is high, but continue evaluating non-variceal causes.
When should TIPS or liver transplantation enter the portal-hypertension pathway?
Pre-emptive TIPS is considered early after haemostasis in validated high-risk bleeds; rescue TIPS treats bleeding uncontrolled by pharmacological and endoscopic therapy, and elective TIPS may help recurrent ascites or rebleeding. Transplant assessment follows decompensation or declining liver function, with cardiac, renal and encephalopathy risks assessed separately.
Inside MedNext for this topic
- 411 MedNext-authored chapters
- 80,000+ MCQ bank
- 15 study modes
- a growing library of visual revision sheets
Study modes
- Notes
- MCQ
- Audio
- Video
- Visual
- 3D Anatomy
- Trace
- Flashcards
- Mnemonics
- Image Bank
- Clinical
- Microscopy
- Audio QBank
- Cadaver
- Book Match
Continue reading
Clinical GuidesAll Clinical Guides
Browse all clinical management guides for Indian medical practice.
Test your knowledge
Attempt structured MCQs on this topic to consolidate your understanding and connect the guide to exam-focused practice.
Try MCQs on this topic